Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Royal DSM N.V.
  6. News
  7. Summary
    DSM   NL0000009827

ROYAL DSM N.V.

(DSM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Royal DSM N : DSM accelerates its strategic journey to a fully focused Health, Nutrition & Bioscience company

09/14/2021 | 01:12am EDT

Heerlen, NL, 14 Sep 2021 07:00 CEST

Royal DSM, a global purpose-led, science-based company, announces its strategic decision to fully focus its resources and capabilities to address the urgent societal and environmental challenges linked to the way the world produces and consumes food. Consequently, DSM is simplifying its operating structure and reorganizing its Health, Nutrition & Bioscience activities into three Business Groups, each with clear opportunities to benefit the health of people and the health of the planet, underpinning DSM's growth plans. At the same time, DSM confirms it has started a review of strategic options for its Materials businesses, including a possible change of ownership.

With a growing global population, the world is facing multiple systemic and interconnected food system challenges that impact the health and wellbeing of people, animals, and the planet. Advancements in digital technology and bioscience offer realistic scalable solutions to tackle these challenges, creating new markets and innovation opportunities. DSM, with its strong combination of scientific competences and growing portfolio of nutrition and health solutions, is ideally positioned to capture these opportunities.

Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: 'Our planet is rapidly approaching critical and irreversible environmental tipping points, as warned in the recent IPCC report. Climate change is already creating huge challenges for food systems worldwide, while at the same time food production remains one of the largest contributors of greenhouse gases. As a global leader in the science behind better health and nutrition, we have the opportunity, capability, and therefore responsibility to apply our resources and expertise where they can have the greatest impact. By focusing exclusively on our health, nutrition and bioscience activities we will be able to operate with greater agility and impact, and meet the growing need for better and more sustainable nutrition'.

DSM will become a fully focused Health, Nutrition & Bioscience company

At the heart of DSM's transformation is the creation of three market-focused Business Groups. Each Business Group will be much closer aligned with their respective customers and, through the integration of activities currently performed by the DSM Innovation Center, will be fully equipped to rapidly develop impactful science-based market-ready innovation. The new Business Groups will be:

  • A Food & Beverage Business Group that combines the food, beverage and pet food activities of the current DSM Food Specialties and DSM Nutritional Products divisions. This Business Group, representing more than €1bn in existing sales, will be uniquely able to meet the needs of customers and consumers by developing sustainable taste, texture, and health solutions. The Business Group's portfolio includes breakthrough innovations such as EverSweet™, a natural calorie-free sweetener, and CanolaPRO®, a plant-based alternative protein. It will also be home to the dairy-based flavorings from First Choice Ingredients, pending regulatory approval of this recently announced acquisition.
  • A Health, Nutrition & Care Business Group with about €2.5bn of sales, aiming to keep the world's growing population healthy through nutrition and care. As the leading player, and in close collaboration with its customers, this Business Group provides unique, sustainable, science-based and innovative solutions for consumers in early-life nutrition, dietary supplements, pharma, medical nutrition, personal care, fragrances, biomedical materials, and nutrition improvement for the most vulnerable communities. It includes a rich innovation portfolio including ampli-D®, the rapid-acting and potent form of vitamin D, an extensive algal lipids portfolio, personalized nutrition initiatives such as Hologram Sciences, as well as Glycom, the world's leading supplier of HMO-prebiotics.
  • An Animal Nutrition & Health Business Group with more than €3bn in existing sales that will focus on specialty solutions for a radical, yet achievable, transformation in the sustainability of animal protein production. Incorporating essential products such as vitamins and carotenoids, the recently acquired Erber Group, one of the world's largest suppliers of eubiotics and market leader in mycotoxin risk management, as well as a wide range of impactful innovations such as methane inhibitor Bovaer® and fish-oil algae-alternative Veramaris. This Business Group also includes precision initiatives with data-driven decision-making tools for famers like Sustell™, and for veterinarians and animal health practitioners like Verax.

DSM will begin reporting according to this new structure as from 1 January 2022. Financial re-statements will be provided prior to the publication of the Q1 2022 trading up-date.

In line with DSM's ambition to have a meaningful impact on improving the world's food systems, the company is also announcing a series of specific new commitments today. They underpin DSM's overarching commitment to meaningfully contribute to Health for People, Health for the Planet and Healthy Livelihoods and span all three new Business Groups. DSM intends to continue to obtain reasonable assurance on its impact reporting, including these new commitments, and plans to report its progress each year in its Integrated Annual Report.

DSM reviews options for its Materials businesses

DSM has two excellent Materials businesses that, within the above context, will likely not be able to maximize their full potential to drive the important industrial shift to a bio-based and circular economy. Going forward the Materials Business Group will therefore be managed largely on a stand-alone basis and the global support functions will be re-aligned accordingly. DSM is reviewing strategic options for both Materials businesses, including a possible change of ownership.

Leadership structure established in line with DSM's strategic vision

DSM's new leadership structure will reflect its strategic vision and the organizational structure of a fully focused Health, Nutrition & Bioscience company.

The Executive Committee, which operates under the Managing Board and is responsible for the day-to-day management of the company, will reflect the new company structure. Next to Co-CEOs Geraldine Matchett and Dimitri de Vreeze, the members will be Helen Mets (Executive Vice President Materials; and Executive Vice President Strategy & Digital), Patricia Malarkey (Chief Science Officer), Cristina Monteiro (Executive Vice President People & Organization), Patrick Niels (Executive Vice President Food & Beverage), Philip Eykerman (Executive Vice President Health, Nutrition & Care; and Executive Vice President M&A), Ivo Lansbergen (Executive Vice President Animal Health & Nutrition), Luca Rosetto (Executive Vice President Operations) and Andre Bos (Executive Vice President Global Products & Strategic Alliances).

As a Health, Nutrition & Bioscience company, DSM has a purpose-led, performance-driven strategy with sustainability and innovation as key growth drivers of its long-term focused plan, underpinned by ambitious targets across People, Planet and Profit. The company recently announced an acceleration in its greenhouse gas emissions reduction target. DSM now aims to reduce emissions from its own operations by 50% by 2030, a significant step-up from the original target of 30% and based on strong progress during recent years.

Disclaimer

Koninklijke DSM NV published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2021 05:11:07 UTC.


ę Publicnow 2021
All news about ROYAL DSM N.V.
10/19Russian petrochemical giant Sibur launches net-zero collaboration platform
AQ
10/19ROYAL DSM N : Completes $453 Million Acquisition Of First Choice Ingredients
MT
10/19ROYAL DSM N : DSM completes the acquisition of First Choice Ingredients
PU
10/19KONINKLIJKE DSM N.V. (ENXTAM : DSM) completed the acquisition of First Choice Ingredients,..
CI
09/14DSM Starts A Review of Strategic Options
CI
09/14ROYAL DSM N : Koninklijke DSM N.V., - DSM accelerates its strategic journey to a fully foc..
PU
09/14Europe ends flat as miners, luxury stocks weigh; inflation optimism cools
RE
09/14ROYAL DSM N : Koninklijke DSM N.V., - DSM announces food system commitments to set a healt..
PU
09/14ROYAL DSM N : DSM prefers direct sale of materials division, CEO says
RE
09/14ROYAL DSM N : Dutch DSM to exit materials to focus on food, health and climate
RE
More news
Analyst Recommendations on ROYAL DSM N.V.
More recommendations
Financials
Sales 2021 8 971 M 10 411 M 10 411 M
Net income 2021 1 353 M 1 571 M 1 571 M
Net Debt 2021 1 108 M 1 286 M 1 286 M
P/E ratio 2021 21,6x
Yield 2021 1,35%
Capitalization 32 188 M 37 303 M 37 354 M
EV / Sales 2021 3,71x
EV / Sales 2022 3,50x
Nbr of Employees 21 173
Free-Float 91,1%
Chart ROYAL DSM N.V.
Duration : Period :
Royal DSM N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYAL DSM N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 188,75 €
Average target price 183,86 €
Spread / Average Target -2,59%
EPS Revisions
Managers and Directors
Dimitri de Vreeze Co-Chief Executive Officer & COO
GÚraldine Matchett Co-Chief Executive Officer & CFO
Thomas Leysen Chairman-Supervisory Board
Eileen A. Kennedy Member-Supervisory Board
Pradeep Pant Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ROYAL DSM N.V.34.06%37 303
SHIN-ETSU CHEMICAL CO., LTD.10.45%70 815
BASF SE-1.96%67 664
DUPONT DE NEMOURS, INC.-2.76%37 623
PIDILITE INDUSTRIES LIMITED34.07%15 730
EVONIK INDUSTRIES AG5.73%15 285